Sfondo Header
L'angolo del dottorino
Search the site... Advanced search
✖

Benign cardiac tumors

Benign cardiac tumors comprise primary cardiac lesions lacking the biological characteristics of sarcomas and other malignant neoplasms, but differing greatly in origin, structure, and behavior. They may develop in the endocardium, on valves, within the myocardium, or in epicardial structures. The designation histologically benign describes the nature of the tissue and does not by itself measure the danger to the patient: a millimeter-sized lesion may cause a stroke, whereas an intramural mass may disrupt electrical conduction or prevent a chamber from filling. Clinical assessment must therefore integrate the identity, location, and functional consequences of the lesion.
The group mainly includes myxoma, papillary fibroelastoma, lipoma, rhabdomyoma, fibroma, and vascular tumors. Some lesions traditionally discussed alongside benign tumors require clarification: lipomatous hypertrophy of the interatrial septum is not a true neoplasm, whereas paraganglioma is a neuroendocrine tumor with metastatic potential and cannot be declared definitively benign solely on its microscopic appearance. This distinction avoids attributing the same natural history to findings that require different strategies.

Primary cardiac neoplasms are rare, and benign forms account for the majority of those diagnosed. Relative frequencies nevertheless depend on age, detection method, and patient selection: a cardiac surgical series favors resected masses, whereas an echocardiography laboratory also recognizes small incidental valvular lesions. The population-based study by Cresti and colleagues, conducted over fourteen years in an Italian area, identified 42 primary tumors, with an overall incidence of 1.38 cases per 100,000 inhabitants per year and a clear predominance of benign forms. This finding documents the rarity of the condition but does not provide a universal estimate for every population.
In adults, cardiac myxoma is the main neoplastic atrial mass, whereas papillary fibroelastoma plays a central role among valvular tumors. Other entities, particularly rhabdomyoma and fibroma, predominate in fetuses and children. Age therefore guides assessment without ruling out unusual presentations or late diagnoses.

Origin, biological classification, and pathogenesis

Most adult forms are sporadic and cannot be traced to a proven modifiable exposure. No set of conventional cardiovascular factors uniformly explains the emergence of benign tumors: hypertension, diabetes, or dyslipidemia may coexist but are not general causes of these neoplasms. Tumor proliferation also encompasses distinct biological situations, from mesenchymal neoplasms to hamartomatous lesions. Pathogenesis must therefore be determined by histologic subtype rather than inferred from cardiac location alone.

Myxomas contain cells embedded in a mucopolysaccharide-rich matrix with vascular structures, hemorrhagic areas, and sometimes surface thrombosis. Origin from mesenchymal cells capable of multiple differentiation pathways is the prevailing model, but the exact initiating cell has not been conclusively identified. The sporadic form usually arises as a single lesion; association with Carney complex, by contrast, introduces a hereditary predisposition often related to pathogenic PRKAR1A variants and altered regulation of protein kinase A. In this setting, multiplicity, early onset, and reappearance at different sites are particularly meaningful, especially with characteristic skin pigmentation or endocrine manifestations.

Fibroelastoma consists of numerous slender, endothelium-covered fronds with a connective tissue core containing collagen and elastic fibers. Its origin remains debated: endocardial changes, microtrauma, and organization of thrombotic material have been proposed, but no hypothesis definitively explains all observations. The branching surface and mobility account for embolic risk even without infiltrative growth. The frequent preservation of surrounding leaflets also helps explain why a potentially emboligenic lesion may produce neither a murmur nor significant regurgitation.

Cardiac lipoma is a localized proliferation of mature adipose tissue, generally encapsulated, that may be subendocardial, intramyocardial, or epicardial. Its impact depends primarily on size and relationships with chambers, coronary arteries, and conduction tissue. Lipomatous hypertrophy of the interatrial septum, in contrast, is a nonencapsulated accumulation of fat with a characteristic distribution sparing the fossa ovalis. Reliable identification of the fat and its distribution often allows the latter finding to be recognized without surgery or sampling, preventing an anatomical variant from being treated as a presumed neoplasm requiring removal.

Cardiac rhabdomyoma is a hamartomatous muscle lesion, frequently multiple, that may be detected during fetal life. Its relationship with tuberous sclerosis arises from abnormal control of mTOR signaling due to TSC1 or TSC2 dysfunction. Possible regression after birth is part of its natural history and makes surgery based solely on the presence of the mass inappropriate. Cardiac assessment should be accompanied by evaluation for other manifestations of the disease when suggested by the context, without assuming that all syndromic signs must be present simultaneously.

Cardiac fibroma is composed predominantly of fibroblasts and collagen matrix and mainly involves ventricular myocardium. Unlike rhabdomyoma, it does not usually regress spontaneously. The relationship between fibrous tissue and residual myocardial bundles may create a substrate for ventricular arrhythmias; benign cellular features therefore do not fully establish prognosis. Some cases are associated with genetic syndromes, including nevoid basal cell carcinoma syndrome, but an isolated fibrous mass alone does not demonstrate a hereditary origin.

The vascular group includes cardiac hemangioma, whose structure is dominated by vascular channels of varying calibers. Intense perfusion on imaging reflects this composition and does not imply malignancy. Cardiac paraganglioma instead originates in paraganglionic tissue, may be richly vascularized, and sometimes secretes catecholamines. Its identification requires appropriate biochemical, genetic, and staging investigations: absence of metastases at diagnosis does not eliminate the need for surveillance. An unplanned biopsy may cause bleeding and, in secreting tumors, catecholamine crises.

Mechanisms of hemodynamic, embolic, and electrical injury

The first mechanism is obstruction. An intracavitary mass may permanently narrow the lumen or move during the cardiac cycle, intermittently interfering with a valve orifice. The gradient depends on the mass volume, its trajectory, heart rate, and cardiac output; consequently, a moderate finding at rest may become more important as flow increases. Obstruction to atrioventricular filling raises upstream pressures, causing pulmonary congestion in left-sided lesions or systemic congestion in right-sided lesions. A sudden fall in output may cause presyncope, syncope, or collapse.

Valve involvement may also cause regurgitation by interfering with coaptation, pulling on leaflets, or causing repetitive mechanical injury. Intramural masses may impair local contractility or reduce available chamber volume; epicardial masses may compress adjacent structures. Not all these effects require a huge lesion: the heart contains narrow passageways and small functional structures where limited growth can have consequences disproportionate to the diameter of the mass.

Embolization results from detachment of fragments of the lesion or thrombi adherent to its surface. Friability and mobility therefore provide information different from size alone. Left-sided masses may cause cerebral, retinal, coronary, or peripheral events; right-sided masses may embolize to the pulmonary circulation. Passage of material from the right heart into the systemic circulation requires communication with right-to-left shunting under the relevant conditions. A sessile intramyocardial mass not exposed to blood does not share the embolic mechanism of a pedunculated valvular lesion.

Arrhythmic injury depends on the location relative to the conduction system and on heterogeneity created within the myocardium. Atrioventricular conduction disturbances, tachycardias, or sustained ventricular arrhythmias may develop. In fibroma, coexistence of fibrous tissue and electrically active myocardium may be the problem; in rhabdomyomas, location and relationships with conduction pathways may contribute. The mass must therefore also be viewed as a possible electrical disorder, particularly when syncope or cardiac arrest is the first manifestation.
An additional level involves mediators. In myxoma, cytokine production, including interleukin-6, may sustain fever, fatigue, and an inflammatory response; in functioning paragangliomas, catecholamine excess may cause hypertension, tachyarrhythmias, and myocardial dysfunction. These effects cannot be explained by anatomical bulk alone and require treatment appropriate to the biology of the lesion.

Clinical manifestations, history, and physical examination

Onset may be incidental or dominated by a single event, such as embolism or syncope. The history reconstructs the development of dyspnea, orthopnea, reduced exercise capacity, edema, and intolerance of particular positions. An intermittent course does not necessarily imply less severe disease: a mobile obstruction can cause episodic symptoms with relatively symptom-free intervals. Sudden palpitations or loss of consciousness without warning require differentiation between an arrhythmic cause and a mechanical reduction in output, because both may coexist.

When the initial problem is neurological, clinicians reconstruct the duration and territory of deficits, any recurrences, and other embolic sources. A cardiac finding compatible with a tumor does not justify automatically attributing every stroke to it: atrial fibrillation, atherosclerosis, and cerebrovascular disease remain possible concurrent causes. Prolonged fever, weight loss, and joint pain may accompany myxoma but also warrant assessment for infections and systemic diseases. Episodes of headache, sweating, and palpitations, particularly with labile hypertension, instead increase concern for catecholamine secretion if mass location and vascularity are consistent.

The family and personal history looks for previous cardiac tumors, unexplained sudden deaths, and syndromic manifestations. In children, prenatal diagnosis, feeding difficulty, failure to thrive, cyanosis, and neurological or skin signs consistent with tuberous sclerosis are relevant. In adults with multiple or recurrent myxomas, characteristic lentiginosis and endocrine disease become important. History taking should be targeted: no family history does not exclude a de novo variant, while one relative with common heart disease does not itself establish a tumor syndrome.

Physical examination assesses heart rate and rhythm, blood pressure, oxygen saturation, and signs of poor perfusion. Auscultation may identify obstructive or regurgitant murmurs and, occasionally, sounds related to mass movement; no finding is sufficiently sensitive to exclude the diagnosis when absent. Congestion is sought in the lungs and systemic circulation, while peripheral pulses, skin, and neurological examination may document embolic sequelae. Pigmented lesions, skin nodules, or endocrine signs complete the examination in appropriate patients.
Many fibroelastomas and lipomas are associated with a normal examination. This is not contradictory: the mass may leave flow unchanged enough to avoid an audible finding while still presenting a risk from mobility or location. Examination establishes the patient's condition and the urgency of further assessment; anatomy is determined by imaging.

Investigations, identification of histologic subtype, and differential diagnosis

Transthoracic echocardiography is generally the first dedicated study. It must document location, number, dimensions, attachment site, and movement, as well as effects on valves, filling, and ventricular function. Doppler permits interpretation of a gradient or regurgitation in its hemodynamic context. Systematic examination of the different chambers is particularly important when multiplicity would alter the diagnosis, as in syndromic disease. A report stating only “benign mass” omits information essential for decision-making.

Transesophageal echocardiography is useful for defining small valvular lesions, atrial stalks, and relationships with the valve apparatus. Three-dimensional imaging may improve understanding of the attachment and planning of valve-sparing resection. Its indication depends on the question, however: it is not mandatory for every already well-documented myocardial lesion but may be decisive when a negative or incomplete transthoracic study fails to explain an embolic event. Transesophageal imaging also has limitations and must be interpreted alongside clinical probability and image quality.

Cardiac magnetic resonance imaging adds tissue characterization. Cine sequences define movement and relationships; weighted and fat-suppressed sequences identify adipose composition; perfusion and late enhancement help assess vascularity and extracellular matrix. A fibroma may show marked late enhancement because of its abundant collagen, whereas myxoma often has heterogeneous features. No single signal feature should be treated as an automatic histologic diagnosis. Very small, highly mobile valvular masses may be less well characterized than on echocardiography, and inconclusive MRI does not exclude them.

Cardiac CT offers high anatomical resolution and accurately identifies fat and calcifications; it helps define relationships with coronary arteries, great vessels, and extracardiac structures, or when MRI is contraindicated or inconclusive. Contrast choice, gating, and acquisition phase should address the clinical question. Nuclear imaging has selected indications: metabolic uptake alone does not distinguish inflammation, a benign tumor, and malignancy, whereas specific functional studies may aid paraganglioma characterization and searches for additional sites.

The differential diagnosis first includes thrombi, vegetations, and pseudomasses. A fibrillating atrium with blood stasis, an akinetic ventricle, or an indwelling catheter changes the likelihood of thrombosis; fever with bacteremia and valvular damage suggests endocarditis. Anatomical variants must be recognized from continuity, location, and movement. Malignant neoplasms become more likely with infiltration, rapid progression, extracardiac invasion, or systemic findings, but absence of these signs is not an absolute guarantee.
Blood tests provide no general marker for benign tumors. Blood counts and inflammatory markers describe the context; blood cultures, hormone measurements, or genetic testing address specific suspicions. No single set of official diagnostic criteria applies to all lesions in the group: the conclusion derives from agreement among clinical findings, imaging, and pathology when available.

Histological examination of resected tissue establishes the lesion type and resolves morphologically overlapping cases. Preoperative biopsy, by contrast, is not automatic: in a mobile emboligenic mass, it may increase risk without changing the indication for removal; in a hypervascular lesion, it can cause bleeding. When tissue diagnosis before treatment is truly necessary, the sampling site and method must be defined by an expert team. Typical radiologic characteristics may be sufficient to monitor some fatty lesions, avoiding procedures with no foreseeable benefit.

Further investigations and individual risk assessment

Once the lesion has been identified, it is necessary to clarify what remains to be determined before choosing treatment. Obstructive risk, mobility, previous embolic events, valve function, and arrhythmias are reassessed. Prolonged electrocardiographic monitoring is appropriate when symptoms or location suggest electrical instability; electrophysiological assessment addresses selected problems and is not a universal test. Serial imaging, when planned, should use comparable measurements because changes in imaging plane can mimic growth.

Surgical planning requires mapping the attachment and relationships with structures that must be preserved. An atrial mass requires attention to the septum and valves; an intramural lesion requires estimation of how much functional myocardium can be spared; a vascularized epicardial mass may require delineation of its coronary blood supply. Coronary assessment is selected according to age, atherosclerotic risk, and the operation involved, without automatically exposing everyone to invasive testing. Existing extracardiac consequences, particularly neurological ones, contribute to perioperative risk assessment.

Genetic investigations focus on relevant phenotypes. When Carney complex is suspected, counseling coordinates family assessment and investigation of extracardiac manifestations; with rhabdomyomas associated with or suggestive of tuberous sclerosis, surveillance includes organs involved in that condition. Molecular findings must be interpreted by distinguishing pathogenic variants from variants of uncertain significance. In paragangliomas, hereditary risk and disease extent are assessed through a dedicated pathway. Routine family genetic screening is not indicated for a common sporadic fibroelastoma.
Typical benign tumors do not require generalized oncologic staging like that for sarcoma. Looking for additional lesions is meaningful when justified by tumor biology, a syndrome, or findings that challenge the initial diagnosis.

Treatment, prognosis, and surveillance

Treatment choice balances the lesion's risk against intervention risk and takes its natural history into account. A mobile emboligenic mass, major obstruction, or a dangerous arrhythmia may necessitate surgical resection even when the lesion is small. Conversely, a stable, well-characterized lesion without functional effects may be suitable for surveillance. The label “benign” does not justify indiscriminate waiting, just as the word “tumor” does not invariably require surgery.

Prompt removal is generally the reference treatment for myxoma because it removes a source of obstruction and embolization. With fibroelastoma, decisions chiefly consider attributable clinical events, left-sided location, mobility, dimensions, diagnostic confidence, and operative risk. Available data mainly come from observational series; proposed size thresholds are not universal boundaries between safety and danger. Where possible, surgery preserves the valve and removes the lesion together with its attachment without fragmentation. Examination of the specimen completes the diagnostic process.

With intramural tumors, the benefit of resection must be balanced against myocardial loss or injury to the conduction system. In fibroma, an arrhythmic presentation may support surgery even without severe obstruction; the extent of removal is adapted to anatomy. Pediatric series demonstrate the possibility of arrhythmia control after resection, but do not justify assuming identical outcomes in every location or size. Lipomas and hemangiomas instead require individualized decisions based on symptoms, growth, compression, and confidence in characterization.

For an asymptomatic or well-tolerated rhabdomyoma, observation is often appropriate because regression may spontaneously change the situation. Critical obstruction, hemodynamic compromise, or uncontrolled arrhythmias require active specialist management. In selected patients, particularly with tuberous sclerosis, mTOR inhibitors may reduce lesion volume; indications, monitoring, and duration depend on clinical circumstances, center experience, and toxicity profile. They are not a general therapy for every benign tumor, and cardiac use requires dedicated assessment.

Supportive treatments manage congestion, arrhythmias, and other consequences but do not replace removal when significant mechanical or embolic risk persists. Anticoagulation may be indicated for associated thrombosis or other conditions, but does not dissolve tumor tissue or guarantee protection from fragment detachment. Endocrinologic preparation precedes procedures in functioning paragangliomas, with a specific hemodynamic strategy. Chemotherapy and radiotherapy are not routine treatments for resectable myxoma or fibroelastoma.

Prognosis is often favorable after effective treatment, but also depends on injury already sustained. A stroke may leave disability despite elimination of its source; concurrent heart disease may limit functional recovery; hereditary predisposition may maintain the risk of new lesions. Subsequent monitoring assesses cardiac function, residual tissue, arrhythmias, and mass recurrence. No single follow-up interval applies to every histologic subtype: frequency and duration are adapted to diagnosis, intervention, syndromic risk, and imaging quality. Recent observations of fibroelastoma recurrence and the greater tendency of syndromic myxomas to recur support thoughtful surveillance even after apparently complete resection.

Complications of disease and treatment

Major complications include cerebral or peripheral embolism, acute obstruction, heart failure, and arrhythmias with hemodynamic compromise. Sudden death may result from different mechanisms that must be recognized to guide prevention: transient blockage of an orifice, ventricular arrhythmia, and coronary involvement are not interchangeable events. In right-sided masses, pulmonary embolism and increased right ventricular workload are additional possibilities. Infection of a lesion and some late vascular complications of myxoma are rare but may radically alter clinical management.

Procedures carry risks of bleeding, embolization, valve injury, conduction disturbances, and ventricular dysfunction, varying with location and operative complexity. A portion intentionally left to preserve vital structures requires an explicit monitoring plan; a new mass detected later must be distinguished from recurrence, a second lesion, or thrombosis. An incorrect diagnosis can itself cause harm through unnecessary anticoagulation, avoidable surgery, or delayed recognition of a malignant tumor. Prevention of complications therefore depends on continuity between initial characterization, multidisciplinary decisions, and long-term surveillance.

References
  1. Tyebally S et al. Cardiac Tumors: JACC CardioOncology State-of-the-Art Review. JACC: CardioOncology. 2020;2(2):293-311.
  2. Basso C et al. Cardiac masses and tumours. Heart. 2016;102(15):1230-1245.
  3. Cresti A et al. Incidence rate of primary cardiac tumors: a 14-year population study. Journal of Cardiovascular Medicine. 2016;17(1):37-43.
  4. Angeli F et al. Multimodality Imaging in the Diagnostic Work-Up of Patients With Cardiac Masses: JACC: CardioOncology State-of-the-Art Review. JACC: CardioOncology. 2024;6(6):847-862.
  5. Lyon AR et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). European Heart Journal. 2022;43(41):4229-4361.
  6. Cohen A et al. EACVI recommendations on cardiovascular imaging for the detection of embolic sources: endorsed by the Canadian Society of Echocardiography. European Heart Journal - Cardiovascular Imaging. 2021;22(6):e24-e57.
  7. Mousavi N et al. Assessment of Cardiac Masses by Cardiac Magnetic Resonance Imaging: Histological Correlation and Clinical Outcomes. Journal of the American Heart Association. 2019;8(1):e007829.
  8. Shenoy C et al. Cardiovascular magnetic resonance imaging in suspected cardiac tumour: a multicentre outcomes study. European Heart Journal. 2022;43(1):71-80.
  9. Kirschner LS et al. Mutations of the gene encoding the protein kinase A type I-alpha regulatory subunit in patients with the Carney complex. Nature Genetics. 2000;26(1):89-92.
  10. Northrup H et al. Updated International Tuberous Sclerosis Complex Diagnostic Criteria and Surveillance and Management Recommendations. Pediatric Neurology. 2021;123:50-66.
  11. Jones JP et al. Ventricular fibromas in children, arrhythmia risk, and outcomes: A multicenter study. Heart Rhythm. 2018;15(10):1507-1512.
  12. Tamin SS et al. Prognostic and Bioepidemiologic Implications of Papillary Fibroelastomas. Journal of the American College of Cardiology. 2015;65(22):2420-2429.
  13. Sorour AA et al. Recurrence of Pathologically Proven Papillary Fibroelastoma. The Annals of Thoracic Surgery. 2022;113(4):1208-1214.
  14. Jiang CX et al. Long-term outcome of patients with atrial myxoma after surgical intervention: analysis of 403 cases. Journal of Geriatric Cardiology. 2019;16(4):338-343.
  15. Jourdan M et al. Constitutive production of interleukin-6 and immunologic features in cardiac myxomas. Arthritis and Rheumatism. 1990;33(3):398-402.

Informational notice: the information contained on this page is provided solely for informational and educational purposes and does not replace the advice, diagnosis or treatment provided by a physician. If needed, always consult a qualified healthcare professional.

Artificial intelligence transparency: this page was created with the support of artificial intelligence tools, used to assist in the production and processing of its content.